ASND
Income statement / Annual
Last year (2023), Ascendis Pharma A/S's total revenue was $266.72 M,
an increase of 421.20% from the previous year.
In 2023, Ascendis Pharma A/S's net income was -$481.45 M.
See Ascendis Pharma A/S’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$266.72 M
|
$51.17 M
|
$7.78 M
|
$6.95 M
|
$13.38 M
|
$10.58 M
|
$1.53 M
|
$4.61 M
|
$8.12 M
|
$13.98 M
|
| Cost of Revenue |
$44.40 M |
$12.14 M |
$3.52 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$222.32 M |
$39.04 M |
$4.26 M |
$6.95 M |
$13.38 M |
$10.58 M |
$1.53 M |
$4.61 M |
$8.12 M |
$13.98 M |
| Gross Profit Ratio |
0.83 |
0.76 |
0.55 |
1 |
1 |
1 |
1 |
1 |
1 |
1 |
| Research and Development
Expenses |
$413.45 M
|
$379.62 M
|
$295.87 M
|
$260.90 M
|
$191.62 M
|
$140.28 M
|
$99.59 M
|
$66.02 M
|
$40.53 M
|
$19.70 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$48.47 M
|
$25.06 M
|
$13.48 M
|
$11.50 M
|
$9.42 M
|
$6.27 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$264.41 M
|
$221.23 M
|
$160.18 M
|
$76.67 M
|
$48.47 M
|
$25.06 M
|
$13.48 M
|
$11.50 M
|
$9.42 M
|
$6.27 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$0.00 |
$0.00 |
| Operating Expenses |
$677.86 M |
$600.85 M |
$456.05 M |
$337.57 M |
$240.09 M |
$165.34 M |
$113.07 M |
$77.53 M |
$49.94 M |
$25.97 M |
| Cost And Expenses |
$722.26 M |
$612.99 M |
$459.57 M |
$337.57 M |
$240.09 M |
$165.34 M |
$113.07 M |
$77.53 M |
$49.94 M |
$25.97 M |
| Interest Income |
$16.86 M |
$52.18 M |
$692,000.00 |
$1.81 M |
$17.80 M |
$4.02 M |
$923,000.00 |
$123,000.00 |
$13,000.00 |
$0.00 |
| Interest Expense |
$44.07 M |
$50.49 M |
$3.91 M |
$1.92 M |
$1.22 M |
$127,000.00 |
$97,000.00 |
$5,000.00 |
$6,000.00 |
$16,000.00 |
| Depreciation &
Amortization |
$18.91 M
|
$17.63 M
|
$16.00 M
|
$8.80 M
|
$6.67 M
|
$908,175.00
|
$689,460.00
|
$710,022.00
|
$558,000.00
|
$504,000.00
|
| EBITDA |
-$438.17 M
|
-$556.04 M
|
-$423.67 M
|
-$328.88 M
|
-$217.03 M
|
-$150.18 M
|
-$109.88 M
|
-$72.12 M
|
-$33.01 M
|
-$11.49 M
|
| EBITDA Ratio |
-1.64 |
-10.3 |
-54.47 |
-47.3 |
-16.23 |
-14.19 |
-71.82 |
-15.66 |
-5.08 |
-0.82 |
| Operating Income Ratio
|
-1.71
|
-10.98
|
-58.09
|
-47.55
|
-16.95
|
-14.63
|
-72.9
|
-15.83
|
-5.15
|
-0.86
|
| Total Other
Income/Expenses Net |
-$18.60 M
|
-$16.00 M
|
$67.85 M
|
-$88.55 M
|
$8.47 M
|
$24.27 M
|
-$12.83 M
|
$4.19 M
|
$8.25 M
|
$1.65 M
|
| Income Before Tax |
-$474.14 M |
-$577.82 M |
-$383.94 M |
-$419.17 M |
-$218.25 M |
-$130.49 M |
-$124.37 M |
-$68.73 M |
-$33.57 M |
-$10.34 M |
| Income Before Tax Ratio
|
-1.78
|
-11.29
|
-49.36
|
-60.29
|
-16.32
|
-12.33
|
-81.29
|
-14.92
|
-4.14
|
-0.74
|
| Income Tax Expense |
$7.30 M |
$5.38 M |
-$367,000.00 |
-$219,000.00 |
-$234,000.00 |
-$394,000.00 |
-$477,000.00 |
-$227,000.00 |
-$652,000.00 |
-$682,000.00 |
| Net Income |
-$481.45 M |
-$583.19 M |
-$383.58 M |
-$418.96 M |
-$218.02 M |
-$130.10 M |
-$123.90 M |
-$68.51 M |
-$32.92 M |
-$9.66 M |
| Net Income Ratio |
-1.81 |
-11.4 |
-49.32 |
-60.26 |
-16.3 |
-12.3 |
-80.98 |
-14.87 |
-4.06 |
-0.69 |
| EPS |
-8.55 |
-10.4 |
-7 |
-8.28 |
-4.69 |
-3.17 |
-3.68 |
-2.58 |
-1.39 |
-0.57 |
| EPS Diluted |
-8.55 |
-10.4 |
-7 |
-8.28 |
-4.69 |
-3.17 |
-3.68 |
-2.58 |
-1.39 |
-0.57 |
| Weighted Average Shares
Out |
$56.29 M
|
$56.07 M
|
$54.77 M
|
$50.62 M
|
$46.51 M
|
$41.09 M
|
$33.63 M
|
$26.56 M
|
$23.68 M
|
$16.94 M
|
| Weighted Average Shares
Out Diluted |
$56.29 M
|
$56.07 M
|
$54.77 M
|
$50.62 M
|
$46.51 M
|
$41.09 M
|
$33.63 M
|
$26.56 M
|
$23.77 M
|
$16.94 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
